25.08.2005 13:09:00

Boston Life Sciences Announces 2005 Annual Meeting of Stockholders

Boston Life Sciences, Inc. (NASDAQ: BLSI) todayannounced that the 2005 Annual Meeting of Stockholders will be held onTuesday, September 13, 2005 at the offices of Wilmer Cutler PickeringHale and Dorr LLP, 60 State Street, Boston, MA 02109 at 10:00am EDT.Stockholders of record at the close of business on August 1, 2005 areentitled to vote at the Annual Meeting. A notice of the Annual Meetingand related proxy materials were mailed to BLSI stockholders.

Due to security at the WCPHD offices, it is requested, but notrequired, that you pre-register for this event. If you plan to attend,please contact Meredith Patin at 508-497-2360 ext. 239 or by email:mpatin@bostonlifesciences.com by Friday, September 9, 2005.

Boston Life Sciences, Inc. (BLSI) is a biotechnology companyprimarily focused on the research and clinical development ofbiopharmaceutical products for the diagnosis and treatment of centralnervous system, or CNS, diseases.

The foregoing release contains certain forward-looking statementswithin the meaning of the Private Securities Litigation Reform Act of1995. Forward-looking statements include statements regarding BostonLife Sciences' expectations, beliefs, intentions or strategiesregarding the future and can be identified by terminology such as"anticipate," "believe," "could," "estimate," "expect," "intend," "isplanned," "may," "should," "will," "will enable," "would be expected,""look forward," "may provide," "would" or similar terms, variations ofsuch terms or the negative of those terms. Such forward-lookingstatements involve known and unknown risks, uncertainties and otherfactors including those risks, uncertainties and factors referred toin the Company's Quarterly Report on form 10-Q for the quarter endedJune 30, 2005, filed with the Securities and Exchange Commission underthe section "Risk Factors," as well as other documents that may befiled by Boston Life Sciences from time to time with the Securitiesand Exchange Commission. As a result of such risks, uncertainties andfactors, the Company's actual results may differ materially from anyfuture results, performance or achievements discussed in or implied bythe forward-looking statements contained herein. Boston Life Sciences,Inc. is providing the information in this press release as of thisdate and does not undertakes any obligation to update anyforward-looking statements contained in this press release as a resultof new information, future events or otherwise.

Our logo, trademarks, and service marks are the property of BostonLife Sciences, Inc. All other trade names, trademarks, or servicemarks are property of their respective owners and are not the propertyof Boston Life Sciences, Inc.

JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.

Nachrichten zu Boston Life Sciencesmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Boston Life Sciencesmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Indizes in diesem Artikel

NASDAQ Comp. 19 954,30 -0,50%